The FDA has approved a novel electroencephalogram device called Minder, developed by Epiminder, to be marketed for patients with drug-resistant epilepsy. The device enables continuous EEG monitoring for extended periods, potentially providing much-needed support for epilepsy management and clinical decision-making. The approval was supported by the UMPIRE trial, demonstrating the device's capacity to offer long-term, ambulatory EEG data of sufficient quality to inform clinical decisions.

Source: Epiminder